News
Orforglipron: What to Know About Eli Lilly’s New Weight Loss Pill for Obesity
Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials. The weight loss pill also significantly improved heart health markers like cholesterol and blood pressure.
On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes ...
Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...
Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven ...
Eli Lilly's pill, orforglipron, is one step closer to becoming the first new, needle-free alternative in the booming market ...
Eli Lilly insiders made notable stock purchases in August, but competitive pressures and pricing risks make me question its ...
While it’s been easy to grow a bit desensitized to the seemingly unstoppable sales growth of Novo Nordisk and Eli Lilly’s | ...
Viking Therapeutics, Inc. (NASDAQ:VKTX) is pressing ahead in the weight-loss drug race with the launch of its Phase 2 VENTURE ...
Eli Lilly & Co.’s experimental pill helped patients shed roughly 11% of their body weight, about 25 pounds, in a late-stage ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback